RecruitingNCT07146451

6-year Outcomes in Children After Nifedipine vs Placebo for Preterm Prelabor Rupture of Membranes at 22-33 Weeks

6-year Follow-up of Children Born to Mothers Exposed to Nifedipine vs Placebo After Preterm Prelabor Rupture of Membranes at 22 to 33 Weeks of Gestation


Sponsor

Assistance Publique - Hôpitaux de Paris

Enrollment

480 participants

Start Date

Oct 28, 2025

Study Type

OBSERVATIONAL

Conditions

Summary

The purpose of this study is to evaluate the neurodevelopment at age 6 of children born to women with preterm prelabor rupture of membranes at 22 to 33 weeks of gestation, after antenatal exposure to nifedipine vs placebo.


Eligibility

Min Age: 6 YearsMax Age: 78 Months

Inclusion Criteria4

  • All children born to mothers enrolled in the TOCOPROM trial who consented to participate in the 2-year follow-up and who agreed to be contacted for the 6-year follow-up
  • Alive at 6 years
  • Internet access, including access to a good-quality video-conference system (only for the psychological evaluation)
  • Non opposition of the holders of the exercise of parental authority

Exclusion Criteria3

  • Major malformations and/or chromosomal aberrations evidenced after birth
  • Impossibility to contact the family
  • Opposition to participate in the follow-up

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHERSelf-administered parental questionnaire

A self-administered parental questionnaire, completed online or on paper, to assess different dimension of neurodevelopment

OTHERA short psychological assessment performed online

NEMI-3: an intelligence test administered by a psychologist measuring a fluid and crystallised intelligence. The test consists of 117 spoken and visual questions, for a total administration time of 45 min. Results are expressed in the form of standard indices (mean 100, standard deviation 15) that facilitate comparisons with the results obtained on other intelligence scales. Results will be classified as normal, mild delay (between 1 and \<2 standard deviation \[SD\] below the mean) or severe delay (≥2 SD).


Locations(1)

Trousseau University Hospital

Paris, France, France

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07146451